Drug-resistance in CML is recognized as a complex and multifactorial process involving mechanisms other than BCR::ABL1 mutation–driven resistance, which can operate individually or together [23, 24]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.